News
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates Lisata Therapeutics Inc (ISIN: US1280583022) with a BUY rating and USD 15.00 price target. Results show operational improvement and positive data on certepetide platform -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Deutsche Effecten- und Wechsel- Beteiligungsgesellschaft AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation on Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG to Buy with a target price of EUR 1.10. Analysis includes H1 2025 results and future outlook -
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. files Form 10-Q for Q3 2025 with SEC, presents NV-387 as broad-spectrum antiviral drug addressing unmet medical needs. Company strengthens financial position with recent financings -
-
-
COMMUNIQUÉ DE PRESSE
Rockhaven Reports Multiple High-Grade Vein Exposures at its Klaza Gold-Silver Project, Yukon
Rockhaven Resources Ltd. reports high-grade gold-silver assay results from the 2025 exploration program at Klaza property, Yukon, advancing towards potential bulk sampling and economic studies